Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study aim to investigate the protected effects of short-term use of dapagliflozin
(administered within 3 days after procedure) in CKD patients after coronary angiography or
percutaneous coronary intervention, as well as observed the incidence of CIN.